Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 26;13:1758835921996673. doi: 10.1177/1758835921996673

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2021

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 2. — Pathologic nodal residual burden in patients with breast pathological complete remission (pCR) and non-pCR.

(a) Percentage of ypN+ in patients with breast pCR. (b) Percentage of ypN+ in patients with breast non-pCR.

*No residual nodal burden in breast pCR patients with the Luminal B (HER2+) or the HER2-amplified subtype.

^#No patients with the Luminal A subtype in the LABC/breast pCR subgroup.

HER2, human epidermal growth factor receptor-2; LABC, locally advanced breast cancer; pCR, pathological complete remission; TNBC, triple-negative breast cancer.